window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

rare diseases

  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    VIVEbiotech expands in vivo lentiviral vector portfolio to 15 programmes

    VIVEbiotech has expanded its in vivo lentiviral vector portfolio to [...]

    June 15, 2026
  • Biotech & Pharma Business,Opinion & Events,Therapeutic Areas

    Chiesi launches second Find For Rare research grants programme at ERA 2026

    Chiesi Global Rare Diseases has launched the second edition of [...]

    June 9, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Allucent adds strategy leaders to expand therapeutic expertise

    Allucent has appointed new therapeutic strategy leaders across key disease [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Cereno Scientific reports long-term safety data from CS1 pulmonary arterial hypertension program

    Cereno Scientific has reported initial long-term safety findings from a [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery

    A new global initiative aims to address long-standing limitations in [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    UMass Chan, Caring Cross and Trenchant BioSystems form sickle cell gene therapy manufacturing alliance

    UMass Chan Medical School, Caring Cross and Trenchant BioSystems have [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    BridgeBio submits FDA NDA for BBP-418 in limb-girdle muscular dystrophy type 2I/R9

    BridgeBio Pharma has submitted a New Drug Application (NDA) to [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Chiesi gains CHMP backing for lomitapide in children with rare cholesterol disorder

    Chiesi Global Rare Diseases has received a positive CHMP opinion [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Polaryx therapeutics selects contract research organization for SOTERIA phase 2 basket trial

    Polaryx Therapeutics, Inc has selected a leading contract research organization [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ZoBio launches DNA-encoded library hit discovery service for difficult drug targets
    Categories: Biotech & Pharma Business, Drug Discovery & Development
  • Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top